The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins

Concetta T. Ammollo; Fabrizio Semeraro; Nicola Semeraro; Mario Colucci

doi:10.1160/TH08-09-0617

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(04): 782-785
DOI: 10.1160/TH08-09-0617

Letters to the Editor

Schattauer GmbH

The contribution of anti-Xa and anti-IIa activities to the profibrinolytic activity of low-molecular-weight heparins

Concetta T. Ammollo

¹Department of Biomedical Sciences and Human Oncology, Section of General and Experimental Pathology, University of Bari, Bari, Italy

,

Fabrizio Semeraro

¹Department of Biomedical Sciences and Human Oncology, Section of General and Experimental Pathology, University of Bari, Bari, Italy

,

Nicola Semeraro

¹Department of Biomedical Sciences and Human Oncology, Section of General and Experimental Pathology, University of Bari, Bari, Italy

,

Mario Colucci

¹Department of Biomedical Sciences and Human Oncology, Section of General and Experimental Pathology, University of Bari, Bari, Italy

› Author Affiliations

Abstract

Full Text

References

References
1 Alban S. From heparins to factor Xa inhibitors and beyond. Eur J Clin Invest 2005; 35 (01) 12-20.
2 Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-2518.
3 Gerotziafas GT, Petropoulou AD, Verdy E. et al. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007; 5: 955-962.
4 Lisman T, Adelmeijer J, Nieuwenhuis HK. et al. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting activated factor X, but not by those inhibiting thrombin or tissue factor. Blood Coagul Fibrinolysis 2003; 14: 557-562.
5 Colucci M, Binetti BM, Tripodi A. et al. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004; 103: 2157-2161.
6 Semeraro F, Piro D, Rossiello MR. et al. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots. Thromb Haemost 2007; 98: 1208-1214.
7 Al Dieri R, Wagenvoord R, van Dedem GW. et al. The inhibition of blood coagulation by heparins of different molecular weight is caused by a common functional motif – the C-domain. J Thromb Haemost 2003; 1: 907-914.
8 Ghosh S, Ezban M, Persson E. et al. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface. J Thromb Haemost 2007; 5: 336-346.
9 Nagashima H. Studies on the different modes of action of the anticoagulant protease inhibitors DX-9065a and Argatroban. II. Effects on fibrinolysis. J Biol Chem 2002; 277: 50445-50449.
10 Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96: 274-284.
11 Schutgens RE, Esseboom EU, Snijder RJ. et al. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism. J Lab Clin Med 2004; 144: 100-107.